Vaxcyte Stock Performance
| PCVX Stock | USD 46.46 0.32 0.69% |
On a scale of 0 to 100, Vaxcyte holds a performance score of 7. The entity has a beta of 0.0776, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Vaxcyte's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vaxcyte is expected to be smaller as well. Please check Vaxcyte's treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to make a quick decision on whether Vaxcyte's existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxcyte are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Vaxcyte showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.93) | Five Day Return 0.44 | Year To Date Return (0.93) | Ten Year Return 76.02 | All Time Return 76.02 |
1 | Is Vaxcyte Inc. stock protected from inflation - Day Trade Weekly Return Optimization Plans - newser.com | 10/24/2025 |
2 | Is Vaxcyte Inc. stock a top hedge fund pick - 2025 Big Picture Scalable Portfolio Growth Methods - newser.com | 11/13/2025 |
3 | Disposition of 74000 shares by Wassil Jim of Vaxcyte subject to Rule 16b-3 | 12/03/2025 |
4 | Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia i... | 12/08/2025 |
5 | Vaxcyte, Inc. Makes Strides on Pneumonia Treatment, Plots Coverage Extension | 12/11/2025 |
6 | Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte | 12/15/2025 |
7 | Disposition of 1000 shares by Elvia Cowan of Vaxcyte subject to Rule 16b-3 | 12/23/2025 |
8 | Insider Selling Vaxcyte SVP Sells 11,623 Shares of Stock - MarketBeat | 12/29/2025 |
9 | Disposition of 9743 shares by Dhaliwal Harpreet S. of Vaxcyte at 46.689 subject to Rule 16b-3 | 12/31/2025 |
| Begin Period Cash Flow | 398.6 M | |
| Total Cashflows From Investing Activities | -2 B |
Vaxcyte Relative Risk vs. Return Landscape
If you would invest 4,074 in Vaxcyte on October 8, 2025 and sell it today you would earn a total of 572.00 from holding Vaxcyte or generate 14.04% return on investment over 90 days. Vaxcyte is currently generating 0.2571% in daily expected returns and assumes 2.9112% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Vaxcyte, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxcyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxcyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaxcyte, and traders can use it to determine the average amount a Vaxcyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0883
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PCVX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Vaxcyte is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaxcyte by adding it to a well-diversified portfolio.
Vaxcyte Fundamentals Growth
Vaxcyte Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxcyte, and Vaxcyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxcyte Stock performance.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 4.46 B | ||||
| Shares Outstanding | 130.91 M | ||||
| Price To Book | 2.10 X | ||||
| Gross Profit | (75 M) | ||||
| EBITDA | (448.08 M) | ||||
| Net Income | (463.93 M) | ||||
| Cash And Equivalents | 354.5 M | ||||
| Cash Per Share | 5.98 X | ||||
| Total Debt | 71.11 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 11.94 X | ||||
| Book Value Per Share | 22.25 X | ||||
| Cash Flow From Operations | (452.63 M) | ||||
| Earnings Per Share | (4.85) X | ||||
| Market Capitalization | 6.08 B | ||||
| Total Asset | 3.51 B | ||||
| Retained Earnings | (1.39 B) | ||||
| Working Capital | 1.65 B | ||||
About Vaxcyte Performance
Evaluating Vaxcyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaxcyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaxcyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (45.64) | (47.93) | |
| Return On Tangible Assets | (0.13) | (0.12) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.13) | (0.12) | |
| Return On Equity | (0.16) | (0.17) |
Things to note about Vaxcyte performance evaluation
Checking the ongoing alerts about Vaxcyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxcyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (463.93 M) with loss before overhead, payroll, taxes, and interest of (75 M). | |
| Vaxcyte currently holds about 354.5 M in cash with (452.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98. | |
| Vaxcyte has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Insider Selling Vaxcyte SVP Sells 11,623 Shares of Stock - MarketBeat |
- Analyzing Vaxcyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxcyte's stock is overvalued or undervalued compared to its peers.
- Examining Vaxcyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxcyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxcyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxcyte's stock. These opinions can provide insight into Vaxcyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.